Fat tissue is often treated as little more than stored energy.

In reality, it is a highly active tissue that constantly communicates with the rest of the body.

That communication depends in part on a dense network of blood vessels.

A new study in Nature Metabolism suggests those blood vessels may be more important in metabolic disease than many people assumed.

Researchers analysed nearly 70,000 vascular cells from fat tissue taken from 65 people.

Using single-cell methods, they built a detailed map of the different endothelial cells that line blood vessels in human fat tissue.

They found far more diversity than expected.

Different vascular cell types appeared to have different specialised roles.

When the team compared healthy tissue with tissue from people with obesity and type 2 diabetes, they found clear differences.

In disease states, the vascular cells had shifted towards patterns linked to inflammation and tissue injury.

That matters because those are two of the main processes involved in metabolic disease.

In other words, the blood vessels may not just be reacting to a bad environment.

They may be helping shape it.

The researchers also identified a previously unrecognised group of cells with mixed features.

These cells seemed to share traits seen in vascular, connective tissue, fat and immune cells.

• Belly fat plus low muscle mass linked to higher death risk
• New diabetes pill could burn fat without harming appetite
• How visceral fat may trigger type 2 diabetes

That suggests more cellular flexibility than expected, which may also matter for how disease develops.

This is still early stage biology rather than a new treatment.

But it points to something important.

If fat tissue blood vessels help drive metabolic dysfunction, then future therapies may need to look beyond hormones and glucose alone.

Weight loss injections such as Wegovy and Mounjaro have changed obesity treatment.

They can help people lose a large amount of weight, often much more than diet and exercise alone achieve in routine practice.

But rapid weight loss is not always just fat loss.

A new review of 36 studies suggests many people on GLP-1 drugs also lose a noticeable amount of lean mass, including muscle.

That matters for more than appearance.

Muscle loss can affect strength, mobility and physical resilience, especially in older adults.

It may also help explain the hollowed facial look that has been dubbed ‘Ozempic face’.

Despite the name, this is not really a separate medical condition.

• Ozempic users continue treatment when weight loss works despite side effects
• Average penis size in the UK has risen due to Ozempic, data suggests
• Weight loss jab Ozempic cuts risk of depression, anxiety and addiction

It is better understood as a visible effect of fast weight loss, particularly when lean tissue and the fat that supports the face are lost alongside body fat.

When someone loses weight quickly, their skin may not shrink back at the same pace.

If muscle and facial fat also drop, the face can look gaunter and more drawn.

The bigger issue is not cosmetic.

The real concern is that muscle loss can leave people weaker and, in some cases, more vulnerable to frailty, falls and loss of independence.

That is especially relevant in older adults, where preserving muscle may matter just as much as reducing weight.

This does not mean the drugs are a bad idea.

For many people, they are highly effective and bring major health benefits.

But they are not a complete treatment on their own.

If someone is prescribed a GLP-1 medicine, they should ideally also get clear advice on diet, protein intake and exercise.

Resistance training is particularly important because it helps preserve muscle while weight is coming down.

That matters both during treatment and after stopping it.

We already know that many people regain weight when they come off these drugs.

• GLP1 drugs commonly cause digestive side effects but may have wider benefits
• GLP-1 medicines: side effects, rare risks and what to monitor
• What happens when patients stop taking GLP-1 drugs

If they have lost muscle as well, that rebound can leave them in a worse position than before.

So the practical message is simple.

These injections can work very well, but they should not be treated as a magic fix.

Weight loss is one thing. Keeping muscle, strength and function while losing weight is another, and that part needs much more attention.

A new study suggests that beer can contain meaningful amounts of vitamin B6, a nutrient involved in brain function, blood health and the immune system.

The vitamin comes from ingredients used in brewing, including barley, wheat and brewer’s yeast.

According to the researchers, the brewing process does not destroy all of it.

The team tested 65 beers bought from supermarkets in Germany.

They found that Bock beer tended to contain the most vitamin B6, while rice beers contained the least.

• Alcohol-free beer linked to increased risk of type 2 diabetes and obesity
• Beer drinkers shown to be healthier and happier in Spain

Average lager in the study provided about 20% of the recommended daily allowance.

Some alcohol-free lagers also performed well, with one sample providing close to 59%.

That sounds impressive at first glance.

But it needs putting in perspective.

Vitamin B6 is found in plenty of ordinary foods, including meat, fish, oats, potatoes, chickpeas and fortified breakfast cereals.

In the UK, true vitamin B6 deficiency is rare.

That is why nutrition experts are not getting carried away by the beer finding.

• Nutrition led rehab scheme aims to support recovery from alcohol dependence
• Ultra-processed foods addiction more likely than alcohol or tobacco addictions among older adults

The message is not that people should start drinking for their vitamins.

It is simply that beer contains more of this nutrient than some people may realise.

If anything, the more useful point may be for alcohol-free beer, which could provide some vitamin B6 without the downsides of alcohol.

Still, if you want to improve your vitamin intake, your diet is the place to start, not the pub.

Scientists at the University of Oklahoma have identified how the hormone FGF21 reduces body weight in mice.

The key finding is that it works through the brain, not mainly through the liver as some might expect.

More specifically, it acts on a circuit in the hindbrain.

That was a surprise to the researchers, who had expected to find the main signal in the hypothalamus, a region more commonly linked to body weight control.

Instead, FGF21 was found to act through two hindbrain regions called the nucleus of the solitary tract and the area postrema.

These regions then signal onwards to the parabrachial nucleus.

• Boosting GLP-1: how to increase GLP-1 levels naturally

According to the researchers, this circuit is essential for the hormone’s ability to reduce body weight.

What makes this especially interesting is that the hindbrain is also the general area where GLP-1 drugs are thought to act.

But the mechanism appears to be different.

GLP-1 drugs such as semaglutide mainly work by reducing appetite and food intake.

FGF21, by contrast, seems to work by raising metabolic activity and increasing the amount of energy the body burns.

That could matter because it points to a different route for weight loss treatment.

Instead of helping people eat less, it may help the body burn more.

The researchers say this could eventually help in the development of more targeted therapies for obesity and for MASH, the serious liver condition previously known as NASH.

• Hormone therapy plus tirzepatide linked to greater weight loss after menopause
• Next generation of obesity jab targets four hormones in quest for lasting weight loss

That said, there is no point pretending this is ready for clinical use.

This was a mouse study, not a human trial.

The researchers also note that FGF21-based drugs can come with side effects, including gastrointestinal problems and, in some cases, bone loss.

So while the biology is genuinely interesting, this is not the discovery of a natural cure for obesity.

It is a useful step in understanding how one hormone affects body weight, and it may help researchers design better treatments in future.

Researchers followed 1,338 older adults for up to 19 years.

Participants wore wrist activity monitors, allowing the researchers to measure napping patterns objectively rather than relying on self-report.

That is important because people are often poor judges of their own sleep and nap habits.

The results showed that longer naps, more frequent naps and morning naps were all associated with a higher risk of death.

Each additional hour of daytime napping per day was linked to roughly a 13% higher mortality risk.

• Diabetes Life Expectancy

Each extra nap per day was linked to around 7% higher risk.

Morning nappers had a 30% higher mortality risk than people who tended to nap in the afternoon.

Notably, irregular napping patterns were not associated with increased mortality.

That makes the picture a bit more specific.

It is not just any nap that seems to matter, but patterns that may reflect poor overnight sleep, circadian disruption or underlying disease.

The key point is that this is correlation, not causation.

The study does not show that napping causes decline.

• Regular napping linked to better health and cognitive benefits
• Sleeping under 7 hours is strongly linked to shorter life expectancy
• Mid-life movement and sleep patterns may hint at lifespan

More likely, excessive or poorly timed napping is acting as a marker of something else going wrong.

That could include neurodegeneration, cardiovascular disease, sleep disorders or general frailty.

So the takeaway is not that older adults should stop napping.

It is that changes in nap length, frequency and timing may be worth paying attention to, especially if they are new.

Researchers compared cortisol levels in 52 female nurses during single and double shifts.

Saliva samples were collected in the morning, after the shift and at midnight.

Cortisol normally follows a circadian pattern.

It tends to be highest in the morning and lowest around midnight.

That basic pattern was still visible in the study.

But the nurses working double shifts showed higher mean cortisol levels overall.

The midnight difference stood out most.

Cortisol was nearly twice as high at midnight in double-shift workers compared with those on single shifts.

That suggests prolonged shifts may put the body under greater physiological stress and interfere with its normal hormonal rhythm.

This matters because cortisol is not just a stress marker in the vague everyday sense.

It is part of the body’s core system for regulating alertness, metabolism and the response to strain.

• Where you live really can shift your weight
• Why night shifts work can raise risk of obesity and type 2 diabetes
• Shift work and diabetes: night shifts

If that pattern is repeatedly disrupted, it may have knock-on effects for sleep, recovery and general health.

The study is small, and it cannot tell us how these cortisol changes play out over years.

It also only looked at female nurses, so the findings cannot automatically be generalised to everyone.

Even so, the result is not particularly surprising.

Long shifts are demanding, and the biology appears to reflect that.

A new clinical trial suggests metformin may still have a role in type 1 diabetes, even if not for the reason many had assumed.

Doctors have sometimes prescribed metformin off-label in type 1 diabetes in the hope that it would improve insulin resistance.

This study found that it did not do that.

But it did show something else that could still matter a great deal to patients.

Adults taking metformin used about 12% less insulin than those taking placebo, while keeping blood sugar control broadly stable.

That is a meaningful finding.

• Type 1 diabetes genetic risk may also be active in brain cells
• Type 1 diabetes: Hybrid closed-loop and open-loop systems compared
• Screening all children for type 1 diabetes is effective

For people with type 1 diabetes, insulin is lifesaving, but it also brings a heavy day-to-day burden.

Anything that safely reduces the amount needed could make management a bit easier.

The trial involved 40 adults with long-standing type 1 diabetes.

Participants were randomised to take either metformin or placebo for six months.

Researchers then used detailed metabolic testing, including clamp studies, to assess insulin resistance in different parts of the body.

They found no clear improvement in insulin resistance and no major change in glucose control.

So the expected mechanism did not hold up.

That is what makes the study interesting.

Metformin seems to be doing something useful, but not in the way researchers thought.

The team now suspects the gut may be involved.

There is growing evidence that metformin acts partly through the gut microbiome, and the researchers are now exploring whether changes in gut bacteria could explain the lower insulin requirement.

• Metformin may mimic some exercise-related metabolic effects in prostate cancer care
• Metformin may lower blood sugar through the brain as well as the body
• Skin cancer risk lowered by metformin

That is plausible, but it remains a theory for now.

The study should also be kept in proportion.

It was small and lasted 26 weeks, so it does not settle the question of whether metformin should be used routinely in type 1 diabetes.

It also does not mean everyone with type 1 diabetes will benefit.

Still, it is a solid and interesting result.

Metformin is cheap, widely available and well known, and if future research confirms that it can safely reduce insulin needs for some people with type 1 diabetes, that could be genuinely useful.

Researchers analysed MRI and diet data from 615 adults in the Osteoarthritis Initiative.

These were people at risk of knee osteoarthritis, but without established radiographic disease or major comorbidities.

The researchers wanted to know whether diets higher in ultra-processed foods were linked to worse muscle composition.

They focused on fat infiltration in thigh muscles.

• Ultra-processed foods linked to lower fertility and slower early embryo development
• Ultra-processed foods in preschool years associated with behavioural difficulties

That is a useful marker because muscle can look normal in size while still becoming poorer in quality if it contains more fat.

The study found that higher ultra-processed food intake was associated with greater fat infiltration across the thigh muscles.

The link remained even after adjusting for BMI.

In fact, the associations were stronger when the researchers adjusted for abdominal circumference instead.

That suggests body fat distribution may be part of the story too.

The result fits with wider concerns about ultra-processed foods.

• Ultra-processed foods engineered to be addictive
• High intake of ultra-processed foods linked to higher death risk in cancer survivors

These diets are often high in salt, sugar, fat and additives, while crowding out nutrient-dense foods that support muscle health, including sources of protein and key micronutrients.

The study cannot tell us whether ultra-processed foods directly damaged muscle.

It also cannot rule out all other explanations.

But it does add another piece to the puzzle.

Poor diet quality may be affecting not just weight and metabolic health, but the quality of muscle tissue itself.

That could matter a great deal as people age, especially when mobility and joint health are already under strain.

A new report in Nature Metabolism makes a clear argument.

Fructose should not be treated as just another source of calories.

The authors say it has distinct metabolic effects that may help drive obesity, insulin resistance and wider metabolic disease.

That matters because fructose is found in many added sugars, including sucrose and high-fructose corn syrup.

It is especially common in sugar-sweetened drinks and heavily processed foods.

• What Fruit Juice Can People With Diabetes Drink?
• Fruit and Diabetes: Can I Eat Fruit?

According to the review, fructose bypasses some of the body’s usual energy regulation steps.

That can promote fat production, drain cellular energy stores and generate by-products linked to metabolic dysfunction.

Over time, those effects may contribute to metabolic syndrome.

The paper also points out something else that is easy to miss.

The body can make fructose internally from glucose, so its role may extend beyond what people eat and drink directly.

That does not mean fructose is uniquely toxic in every form.

The main concern here is not whole fruit.

Whole fruit comes with fibre, water and a very different nutritional package.

The problem is mainly fructose consumed as part of free sugars in modern diets.

• Fructose and inflammation: sweetener that may make infections harder to fight
• Fruit, coffee, chocolate and wine may reduce risk of metabolic syndrome by 23%

The broader argument is not especially radical.

In an environment where cheap, sweet, energy-dense food is constantly available, a metabolic pathway that once helped humans survive scarcity may now be helping drive chronic disease.

That is plausible and worth taking seriously.

Still, this is a review article.

It helps frame the biology, but it does not settle every debate about sugar, nor does it prove fructose is solely responsible for rising metabolic disease.

Researchers reviewed 27 prospective studies involving more than 4 million people.

All participants were free of mental or neurocognitive disorders at the start, then followed over time.

The question was simple.

Did fitter people go on to develop fewer mental health problems?

Overall, the answer appeared to be yes.

Higher cardiorespiratory fitness was linked to a 36% lower risk of depression, a 39% lower risk of dementia and a 29% lower risk of psychotic disorders.

There was also a possible link with lower anxiety risk, but that result was weaker and not statistically convincing.

• Compound Exercises: How They Help Support Healthy Aging

One of the more useful findings was that the benefit did not seem to require dramatic changes.

A one-MET increase in fitness, which is a fairly modest improvement, was linked to a roughly 5% lower risk of depression and a 19% lower risk of dementia.

That matters because it suggests the potential gains are not just for runners or gym enthusiasts.

They may be relevant at population level.

This is also a stronger type of evidence than the usual cross-sectional study, because the researchers looked at prospective cohorts.

• Metformin may mimic some exercise-related metabolic effects in prostate cancer care
• Mid-life movement and sleep patterns may hint at lifespan
• Inactivity may drive up to 10% of major type 2 diabetes complications

Even so, it is still observational evidence.

That means it cannot prove that low fitness causes these conditions, or that raising fitness will definitely prevent them.

But the overall message is still important.

Cardiorespiratory fitness looks like a meaningful, measurable and modifiable marker that may have a role in mental health and brain health prevention.

A new specialist mental health pathway for people with diabetes is being developed in Wales, in what experts say is a UK first.

The aim is to offer more joined-up support for people whose mental health and diabetes management are closely tied together.

For many patients, that gap in care has been a serious problem.

Naomi Durham, from Cardiff, said severe post-natal depression after the birth of her second daughter left her feeling numb and hopeless.

At her lowest point, she stopped taking the insulin she needed for her type 1 diabetes.

That led to repeated admissions to hospital with diabetic ketoacidosis, a life-threatening complication caused by a lack of insulin.

She said she felt caught between two systems.

The diabetes team treated it as a mental health issue, while mental health services treated it as a diabetes issue.

• Type 1 diabetes genetic risk may also be active in brain cells
• Type 1 diabetes: Hybrid closed-loop and open-loop systems compared

In practice, that meant she did not feel properly supported by either.

Naomi said peer support groups, online communities and charity services ended up helping more than formal services at the time.

But she still believes people in her position need better holistic assessment and clearer routes into the right help.

Poet Duke Al described a different but related experience.

After being diagnosed with type 1 diabetes, he said the condition collided badly with his existing OCD.

At times, intrusive thoughts around numbers led him to inject the wrong amount of insulin or avoid injecting altogether.

He said diabetes burnout and the constant demand of managing blood sugar, insulin, food and exercise became overwhelming.

Although he now feels in a much better place, he said there was not a huge amount of mental health support available that really understood diabetes.

That lack of joined-up care is exactly what the new pathway is supposed to address.

Dr Rose Stewart, diabetes psychology lead for Wales, said diabetes is relentless and can have a huge psychological impact.

She said many people feel as if they are being asked to do the work of their own pancreas around the clock, without ever getting a break.

• Find support from people with diabetes in the Diabetes Forum
• What is Diapression?

Her team is developing a national model of care that would give people in Wales quicker access to specialist support in different formats.

That could include online help, one-to-one therapy and crisis care, as well as training for diabetes staff so they are better equipped to deal with psychological distress.

The broader point is straightforward.

You can have a good HbA1c and still be struggling badly.

Equally, poor diabetes management is not always just about knowledge or motivation – sometimes it is bound up with depression, burnout, fear, trauma or obsessive thinking.

This new pathway matters because it treats the person as a whole, rather than trying to split physical health from mental health when, for many people with diabetes, the two are inseparable.

A study presented at this year’s European Congress on Obesity suggests men and women with obesity may not carry the same hidden health risks.

Researchers analysed data from more than 1,100 adults treated at an obesity clinic in Turkey.

They found that men tended to have larger waist circumferences, higher systolic blood pressure and higher levels of liver enzymes and triglycerides.

That points towards a greater burden of visceral fat and a higher likelihood of liver and metabolic complications.

Women, by contrast, had higher total cholesterol and LDL cholesterol.

They also showed higher levels of inflammatory markers such as C-reactive protein, erythrocyte sedimentation rate and platelet count.

That suggests a stronger inflammatory profile.

The overall message is not that obesity is worse in one sex than the other.

It is that the pattern of risk may differ.

Men appeared more likely to show the kind of fat distribution associated with visceral obesity and metabolic disease.

Women appeared more likely to show raised inflammation and less favourable cholesterol profiles.

There are plausible biological reasons for that.

Hormones influence where fat is stored, how the liver handles nutrients and how the immune system behaves.

Women also tend to have a more active immune response, which may partly explain the higher inflammatory markers.

• Hidden immune loop may drive dangerous inflammation with age
• Natural brakes on inflammation could lead to new treatments for chronic disease
• Calming inflammation may help prevent early macular degeneration

This matters because obesity is often treated too generically.

If the underlying biology differs by sex, then the risk assessment and possibly the treatment approach may need to differ as well.

That said, this is not the final word.

The study was cross-sectional, so it cannot show cause and effect.

Most participants were also from one ethnic background, so it may not translate neatly to other populations.

Still, it is a useful reminder that obesity is not one-size-fits-all, and neither is the risk that comes with it.

The government has announced plans to tighten the rules on school food in England.

Under the proposals, deep-fried food would be banned from school dinners and sugary desserts would be limited to once a week.

Schools would also be expected to serve more fruit, vegetables and wholegrains.

One aim is to cut back on the kind of quick, unhealthy options that can easily become routine, such as pizza or sausage rolls every day.

Ministers say the changes are designed to improve children’s health and help millions of pupils get more nutritious meals at school.

The government is presenting this as the biggest overhaul of school food in a generation.

It says the current rules have not been updated for a decade and that progress was delayed by the pandemic.

The plans will apply to primary and secondary schools in England.

A consultation will run for nine weeks, with final standards due to be confirmed in September.

If approved, the new rules would come into force from September 2027.

Schools would also be expected to publish menus online.

A new enforcement system is being planned to check whether schools are actually following the standards.

The policy fits with wider moves on school food.

From September 2026, all children in England whose parents receive Universal Credit will be able to claim free school meals.

The government has also expanded funding for breakfast clubs after concerns that the previous amount was not enough.

• Ultra-processed foods in preschool years associated with behavioural difficulties
• High intake of ultra-processed foods associated with lower grades in school
• Prue Leith: Obesity rates could fall if schools teach students how to cook healthy meals

The main argument against the plans is not really about nutrition.

It is about money.

School leaders and caterers have repeatedly said the funding for school meals does not match the true cost of providing them.

That has already led, in some cases, to smaller portions and poorer quality ingredients.

So while few people are openly defending deep-fried school food, there is still a serious practical question.

If schools are expected to serve healthier meals, someone has to pay for it.

Researchers in China studied CBD in triple-transgenic mice designed to develop Alzheimer’s-like pathology.

These mice accumulate tau and beta-amyloid, develop synaptic damage and show memory problems.

After 45 days of treatment, the mice performed better on behavioural testing.

They also showed lower anxiety-like behaviour and signs of restored synaptic structure.

That alone would have been enough to attract attention.

But the researchers went further and tried to work out how CBD was doing this.

They found evidence that CBD binds directly to a protein called FRS2.

Rather than acting like a classic lock-and-key drug, CBD appeared to stabilise the interaction between FRS2 and another protein, TrkB.

The researchers describe this as a kind of molecular glue.

That matters because the TrkB pathway is involved in neuronal survival and plasticity.

When they reduced FRS2 in the mice, CBD lost much of its apparent protective effect.

That strengthens the case that the pathway is relevant.

Still, it is important not to get carried away.

• Exposure to fine particulate air pollution leads to a higher risk of developing Alzheimer’s
• Youth-onset diabetes linked to higher risk of Alzheimer’s disease in later life, research suggests
• Alzheimer’s disease can be identified years before diagnosis, research shows

This is an animal study in a genetically engineered model.

Mouse findings often look promising and then fail to translate into meaningful results in people.

The paper is valuable because it adds mechanistic detail and points to a potentially druggable pathway.

But it does not show that CBD reverses Alzheimer’s disease in humans, and it certainly does not justify treating over-the-counter CBD products as proven therapy.

At this stage, the most accurate description is that CBD showed neuroprotective effects in mice and opened up an interesting line of research.

That is worth noting, but it is not the same thing as a treatment breakthrough.

GLP-1 drugs were developed for diabetes, but they are now widely used in obesity treatment as well.

A new umbrella review examined what these medicines do beyond blood sugar, weight and cardiometabolic disease.

Researchers pulled together 60 meta-analyses covering more than 1,700 randomised clinical trials and over 3.5 million participants.

The most reliable finding was not surprising.

GLP-1 receptor agonists were strongly associated with gastrointestinal side effects, especially nausea, diarrhoea and vomiting.

That fits with what clinicians and patients already know from day-to-day use.

• Boosting GLP-1: how to increase GLP-1 levels naturally

The more interesting part of the review was what lay beyond that.

The researchers found possible signals that GLP-1 drugs might reduce the risk of some serious infections and offer benefits for lung health, bone outcomes and dementia-related pathways.

There are plausible reasons for some of those effects.

Weight loss can improve sleep apnoea and respiratory function. Reduced inflammation may also play a part.

• GLP1 weight loss drugs linked to small rise in chronic cough
• Daily GLP1 pill helps people lose around 10% of their body weight
• Most adults stop GLP1 therapy within a year

But that is where caution matters.

These possible benefits were not supported by the same level of certainty as the digestive harms.

The authors were clear that stronger evidence is needed before GLP-1 drugs are seriously considered for infections, dementia or other non-cardiometabolic uses.

So the practical message is fairly straightforward.

GLP-1 drugs do have a broader biological footprint than just weight and glucose, but the only thing you can say with confidence right now is that digestive side effects are common and need monitoring.

The rest is interesting, but not settled.

Type 1 diabetes is usually described as an autoimmune disease in which the immune system attacks insulin-producing cells in the pancreas.

That is true, but a new study suggests the story may be broader than that.

Researchers found that genetic variants linked to type 1 diabetes risk are also active in certain brain cells.

The most important signal appeared in microglia, which are the brain’s resident immune cells.

That matters because some people with type 1 diabetes report cognitive symptoms such as brain fog, slower processing or memory lapses.

These problems are often blamed on blood sugar swings alone.

This study suggests there may be something deeper going on.

The researchers used large population datasets, including the UK Biobank, to compare around 20,000 people with type 1 diabetes with roughly 500,000 without it.

They then mapped the relevant genetic signals across different brain cell types.

The overlap with microglia stood out.

The researchers also used Mendelian randomisation to explore whether genetic liability linked to cognitive traits was associated with type 1 diabetes risk.

They found evidence of shared pathways, although not a simple cause-and-effect relationship.

• Type 1 diabetes: Hybrid closed-loop and open-loop systems compared
• Screening all children for type 1 diabetes is effective
• Plant-based eating may help some people with type 1 diabetes use less insulin

That is the key point.

This is not proof that type 1 diabetes causes cognitive difficulties, or that brain changes drive diabetes directly.

It is evidence that both may be influenced by some of the same biological architecture.

That shifts the way type 1 diabetes is framed.

Instead of thinking about it only as a pancreas-and-immune-system disease, this work points towards a more systemic view that includes neuroimmune interactions too.

That does not change day-to-day treatment yet.

But it may eventually help explain why some people with type 1 diabetes struggle cognitively even when glucose is not the whole story.

Researchers at the University of Miami looked at how metformin affects a molecule called N-lactoyl-phenylalanine, or Lac-Phe.

Lac-Phe has drawn attention because levels rise after intense exercise and may be linked to appetite regulation and energy balance.

The study found that metformin increased Lac-Phe in men with prostate cancer, even when they were not exercising at the time.

That matters because hormone therapy for prostate cancer often disrupts metabolism.

Patients can gain weight, develop insulin resistance and face a higher cardiovascular burden.

At the same time, fatigue and other treatment effects can make regular exercise harder.

So the question the researchers asked was a practical one.

Could a commonly used drug activate some of the same metabolic pathways associated with exercise, even when people are less able to move?

The answer appears to be yes, at least in part.

Importantly, the study did not find that higher Lac-Phe levels were linked to better tumour response.

This is not a cancer control story.

• Metformin may lower blood sugar through the brain as well as the body
• Metformin and Alcohol: Effects of Drinking When Taking Metformin
• Metformin may reduce long COVID risk when taken early in infection

It is a metabolic support story.

That distinction matters because the benefit, if confirmed, may lie in helping patients cope better with treatment rather than directly shrinking disease.

The study also found that Lac-Phe tracked more closely with weight change than another metformin-linked molecule, GDF-15.

That suggests metformin may influence body weight through several pathways, with Lac-Phe being one of them.

The broader takeaway is sensible.

Cancer treatment affects far more than the tumour, and supporting metabolic health can be clinically meaningful even when it does not alter PSA or disease progression directly.

Researchers from Mass General Brigham studied more than 136,000 adults from two long-running cohort studies.

All participants had a BMI above 25 at baseline.

To estimate long-term exposure to excess weight, the researchers averaged BMI measurements over a ten-year period.

They then followed participants for cardiovascular outcomes for an average of 16.7 years.

During follow-up, more than 12,000 people experienced events such as heart attack or stroke.

The study found that cumulative exposure to excess weight was more strongly linked to cardiovascular risk than a single BMI reading.

That is an important distinction.

A one-off BMI gives a snapshot. Long-term exposure tells you more about the actual burden placed on the body over time.

The strongest effects were seen in younger groups.

For example, women younger than 35 at baseline had a 60% higher cardiovascular risk with high cumulative exposure to excess weight.

The increase was smaller in older groups and was not seen in women over 50 or men over 65.

• Hormone therapy plus tirzepatide linked to greater weight loss after menopause
• Weight loss jab Ozempic cuts risk of depression, anxiety and addiction
• Weighted vests prevent metabolic slowdown during weight loss

That may reflect the fact that excess weight earlier in adult life has longer to do harm.

It also reinforces a practical message.

Risk is not set in stone by one reading.

Weight history matters and reducing excess weight exposure over time may still improve outcomes.

That makes this a more useful and more humane way of thinking about risk than treating BMI as a permanent label.

A new study suggests vitamin D status in mid-life may be linked to brain health years later.

Researchers followed 793 adults who were free of dementia at the start of the study.

Participants were around 39 years old on average when their vitamin D levels were measured.

About 16 years later, they had brain scans to assess tau and amyloid beta, two proteins linked to Alzheimer’s disease.

The key result was that people with higher vitamin D levels in mid-life had lower levels of tau later on.

That is potentially important because tau accumulation is strongly associated with neurodegeneration and cognitive decline.

The study did not find the same relationship with amyloid beta.

That makes the result more specific, but also more complicated.

It suggests vitamin D may be linked to some aspects of Alzheimer’s biology and not others.

As ever, there are limits.

Vitamin D was measured only once, so the study cannot tell us what happened to levels over time.

It was also observational, which means it shows a link, not proof that vitamin D itself changed the brain outcome.

• Vitamin D3 may halve the risk of a second heart attack
• Vitamin D2 may impair the more efficient virus-busting vitamin D3
• Type 2 diabetes risk not lowered by high-dose vitamin D supplements

Still, the study makes a fair point.

Mid-life is often when risk factors can still be modified, so it is a sensible stage to look at things like vitamin D, blood pressure and metabolic health.

The big mistake would be to oversell it.

This is not evidence that vitamin D supplements prevent dementia.

It is a useful signal that deserves further study.

A large cohort study from Italy looked at whether wine drinking patterns were linked to biological ageing.

Researchers analysed data from more than 22,000 adults in the Moli-sani study.

Instead of looking only at chronological age, they estimated biological age using a machine learning model based on 36 blood biomarkers.

They then compared biological age with actual age to see whether some people appeared to be ageing faster or more slowly.

The main finding was that men who drank moderate amounts of wine in line with a traditional Mediterranean diet had slightly lower biological ageing scores than abstainers.

• High intake of white wine associated with increased risk of skin cancer – but not red wine
• Fruit, coffee, chocolate and wine may reduce risk of metabolic syndrome by 23%

The strongest association was seen at around 170 mL a day, which works out at roughly one to two small glasses.

The effect was modest.

At its peak, the difference was about a third of a year.

That is interesting, but it is hardly a dramatic anti-ageing result.

The study did not find the same clear pattern in women.

It also found that total alcohol intake from all sources did not show the same association as moderate wine intake.

That raises the possibility that any observed effect may be related to broader drinking patterns or to compounds in wine rather than alcohol itself.

• Ageing does not always mean decline
• Regular aerobic exercise may slow brain ageing in midlife
• Live to 100: 5 habits linked with healthier ageing

Even so, this needs careful handling.

People in the moderate drinking group also tended to be healthier in other ways, although the researchers adjusted for a range of lifestyle and health factors.

That means the findings are worth noting, but they do not prove cause and effect.

So the sensible reading is this.

The study adds to the literature around Mediterranean dietary patterns and healthy ageing, but it does not justify telling people to drink wine for their health.